The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 26, 2016

Filed:

Apr. 20, 2012
Applicants:

Lin Mei, Evans, GA (US);

Wen-cheng Xiong, Evans, GA (US);

Bin Zhang, Evans, GA (US);

Chengyong Shen, Augusta, GA (US);

Inventors:

Lin Mei, Evans, GA (US);

Wen-Cheng Xiong, Evans, GA (US);

Bin Zhang, Evans, GA (US);

Chengyong Shen, Augusta, GA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/00 (2006.01); C07K 1/00 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2006.01); G01N 33/564 (2006.01); G01N 33/92 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C12Q 1/6883 (2013.01); G01N 33/564 (2013.01); G01N 33/92 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/28 (2013.01); G01N 2800/38 (2013.01);
Abstract

The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.


Find Patent Forward Citations

Loading…